Saturday 17 October 2026
Export ELAB’s income statement to Excel — free account
PMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023. In the quarter to June 2026, revenue grew 147.7%, EPS grew 98.4% and free cash flow fell 45.0%, each against the same quarter a year earlier.
2.77
0.27
−8.88%
Follow ELAB
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 1,815,579.00 | 10,256.84 | 300.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 5,003,452.50 | 4,586,105.50 | 23,991.58 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 16 | 18 | 3 | 34 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.05 | 0.10 | 0.00 | 0.02 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 2 | — | 1 | ||||
| Gross margin, % | — | — | — | — | — | — | 58.37 | 66.25 | — | 31.40 | |||||
| EBT | — | — | — | — | — | — | (2) | (2) | (4) | (8) | |||||
| EBT margin, % | — | — | — | — | — | — | (234.93) | (96.74) | 0.00 | (1,313.30) | |||||
| Net income | — | — | — | — | — | — | (2) | (4) | (6) | (8) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.08 | 0.00 | 0.00 | 295.05 | ||||
| Earnings | — | — | — | — | — | — | (0.19) | (470,188.30) | (65,913.31) | (3,806.90) | |||||
| Cash flow | — | — | — | — | — | — | (0.17) | 0.00 | (54,870.00) | (2,966.95) | |||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | (4,715.00) | (224.15) | |||||
| Free cash flow | — | — | — | — | — | — | (0.17) | 0.00 | (59,585.00) | (3,191.10) | |||||
| Book value | — | — | — | — | — | — | 0.12 | 0.00 | 66,596.00 | 3,918.70 | |||||
| Shares, m | — | — | — | — | — | — | 10 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | ||||
| P/S | — | — | — | — | — | — | 27,782,590.20 | 0.00 | — | 0.41 | |||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.09 | |||||
| EV/Sales | — | — | — | — | — | — | 27,782,589.87 | (1.94) | — | (3.01) | |||||
| EV/FCF | — | — | — | — | — | — | (14,963,278.66) | 0.73 | — | 0.81 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (2) | (5) | (5) | (6) | ||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (2) | (5) | (6) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 1 | 4 | 4 | 3 | ||||
| Total debt | — | — | — | — | — | — | — | — | 1 | 0 | |||||
| Net debt | — | — | — | — | — | — | (1) | (3) | (3) | (6) | |||||
| Shareholders’ equity | — | — | — | — | — | — | 1 | 4 | 7 | 8 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (121.48) | (88.07) | (70.88) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | (142.57) | (71.34) | (220.80) | |||||
| ROE | — | — | — | — | — | — | 0.00 | (173.52) | (119.12) | (106.89) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
PMGC Holdings Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| XRTX XORTX Therapeutics Inc. | $2.6M | — (loss-making) | — | — | n/m | −318.40% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| EIGRQ Eiger BioPharmaceuticals, Inc. | $2.6M | — (loss-making) | — (loss-making) | +41.06% (above 0%: growing) | n/m | +37.90% (above 0%: growing) | 97.34% | (331.69%) | Compare |
| BIORQ Biora Therapeutics, Inc. | $2.5M | — (loss-making) | — (loss-making) | +1,500.00% (above 0%: growing) | n/m | +20.72% (above 0%: growing) | 100.00% | (50,709.38%) | Compare |
| ELAB PMGC Holdings Inc. | $2.5M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | |
| NTBLQ Notable Labs, Ltd. | $2.4M | — (loss-making) | — (loss-making) | −96.88% (below 0%: shrinking) | n/m | −26.63% (below 0%: shrinking) | 100.00% | (269,000.00%) | Compare |
| VBIO Valion Bio, Inc. | $2.4M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $2.4M | — (loss-making) | — (loss-making) | +365,433.33% (above 0%: growing) | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BPTSY Biophytis SA Sponsored ADR | $2.4M | — (loss-making) | — | — | n/m | +53.15% (above 0%: growing) | 0.00% | — | Compare |
| WINT Windtree Therapeutics, Inc. | $2.4M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +1.12% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $2.4M | — | — | +28.47% | — | +5.14% | 0.00% | 0.00% |
PMGC Holdings Inc. (ELAB) key facts
- Concern: PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023.
- PMGC Holdings Inc. (ELAB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ELAB traded at $2.77, a market capitalization of $2.5 million.
- Return on equity was −106.9% and debt-to-equity 0.02.
- Its Altman Z-score is −3.65 (distress zone) for fiscal 2025.